Medical Literature

  1. The medical literature cited in the task force report

Other

  1. Transcripts and minutes of the three advisory committee meetings on the drug

  2. FDA's Biopharmaceutic reviews of the NDA

We understand that physicians' and patients' names will not be disclosed to the public.

Kenneth F. King, Ph.D.

Vice President, Regulatory Affairs

Pharmacia & Upjohn Company

Date



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement